Tag: Inscripta™

Inscripta raises $125M for Genome Engineering platform

Inscripta raises $125M for Genome Engineering platform

December 16, 2019 |

In Colorado, Inscripta raised $125 million in a Series D financing with support from the company’s existing investors and new investors JS Capital Management LLC and Oak HC/FT. Paladin Capital Group led the round, bringing the total amount raised by the company to $259.5 million. The new funds will be used to accelerate applications expansion […]

Read More

Colorado start up announces $125 million capital rise for genome-scaling technology

Colorado start up announces $125 million capital rise for genome-scaling technology

December 12, 2019 |

In Colorado, Inscripta, Inc., announced the company has raised $125 million in a Series D financing with support from the company’s existing investors and new investors JS Capital Management LLC and Oak HC/FT. Paladin Capital Group led the round, bringing the total amount raised by the company to $259.5 million. The new funds will be […]

Read More

Inscripta™ says proprietary CRISPR enzyme achieved wide adoption during first year on the market

Inscripta™ says proprietary CRISPR enzyme achieved wide adoption during first year on the market

January 1, 2019 |

In Colorado, Inscripta™, a leading gene-editing technology company, announced that MAD7, its proprietary CRISPR enzyme, has achieved wide adoption by academic, commercial, and government researchers in its first year of availability. MAD7 was recently recognized by the Scientist magazine as one of the “Top 10 Innovations of 2018.” To build on the progress that Inscripta […]

Read More